I spoke to Jonathan Martin of the New York Times about a major prescription drug deal between the Trump Administration and the pharmaceutical industry that fell apart over late White House demands for “Trump Cards” that would be distributed to seniors in the home stretch of the campaign. Given the way things are going with the campaign, it’s no surprise that they’re passing up first downs and shooting for the end zone.
Even more puzzling is why the White House would not have taken a victory in hand that would have let the president extol his negotiating skills and crow about delivering for seniors.
Instead, they unveiled an executive order on a weekend that drew little coverage and is far harder for people to grasp than industry-subsidized cost relief for consumers.
“It’s objectively imprudent,” said Liam Donovan, a Republican strategist. “But when you need to change the trajectory of the race, you have to be willing to take risks.’’
Click here to read the full piece.